Zhejiang Cheng Yi Pharmaceutical Co (SHSE:603811) Net Income From Continuing Operations : ¥165.6 Mil (TTM As of Sep. 2024)

View and export this data going back to 2017. Start your Free Trial

What is Zhejiang Cheng Yi Pharmaceutical Co Net Income From Continuing Operations?

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. Zhejiang Cheng Yi Pharmaceutical Co's net income from continuing operations for the three months ended in Sep. 2024 was ¥40.5 Mil. Its net income from continuing operations for the trailing twelve months (TTM) ended in Sep. 2024 was ¥165.6 Mil.

Zhejiang Cheng Yi Pharmaceutical Co Net Income From Continuing Operations Historical Data

The historical data trend for Zhejiang Cheng Yi Pharmaceutical Co's Net Income From Continuing Operations can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Zhejiang Cheng Yi Pharmaceutical Co Net Income From Continuing Operations Chart

Zhejiang Cheng Yi Pharmaceutical Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Net Income From Continuing Operations

Get a 7-Day Free Trial

130.96

164.95

171.23

161.18

162.05

Zhejiang Cheng Yi Pharmaceutical Co Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Net Income From Continuing Operations	Get a 7-Day Free Trial															23.20	48.55	32.73	43.79	40.49

Zhejiang Cheng Yi Pharmaceutical Co Net Income From Continuing Operations Calculation

Net Income From Continuing Operations indicates the net income that a firm brings in from ongoing business activities. These activities are expected to continue into the next reporting period. It excludes extraordinary items, income from the cumulative effects of accounting changes, non-recurring items, income from tax loss carry forward, and preferred dividends.

Net Income From Continuing Operations for the trailing twelve months (TTM) ended in Sep. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ¥165.6 Mil.

Zhejiang Cheng Yi Pharmaceutical Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Zhejiang Cheng Yi Pharmaceutical Co Ltd (SHSE:603811) » Definitions » Net Income From Continuing Operations

Traded in Other Exchanges

N/A

Address

No. 118, Chemical Road, Dongtou District, Zhejiang Province, Wenzhou, CHN, 325700

Website

http://www.chengyipharma.com

Zhejiang Cheng Yi Pharmaceutical Co Ltd is a pharmaceutical company that produces capsules, injections, tablets, APIs, and pharmaceutical intermediates in China. Its main products include glucosamine hydrochloride raw materials and preparations, torasemide injection and capsules, Gastrodin raw materials, ribavirin and purine raw materials, and so on.

Executives

Ke Ze Hui	Director
Ren Bing Jun	Director
Yan Yi Yi	Director
Ceng Huan Qun	Director
Li Shi Sheng	Director
Qiu Ke Rong	Director
Lv Sun Zhan	senior management
Zhang Gao Qiao	Supervisors
Zhang Zhi Hong	senior management
Mao Li Ping	senior management
Zhuang Xiao Ping	Director
Lin Xin Chen	senior management
Shen Ai Lan	Director
Zhang Fu Fu	Supervisors

Zhejiang Cheng Yi Pharmaceutical Co Headlines

No Headlines